# Dr Reddys Laboratories Ltd (DRREDDY)
> Exchange: NSE | Sector: Pharma | ISIN: INE089A01031

## Price
Current Price: ₹1307.2
Day Change: -0.86%
52W High: ₹1377.95
52W Low: ₹1025.9
Market Cap: ₹1,11,310 Cr

## Valuation
P/E: 19.71
P/B: 2.99
EPS: ₹67.84
Book Value: ₹452.27
Dividend Yield: 0.61%

## Returns
1Y Return: 5.05%

## Profitability
ROE: 11.84%
ROCE: 20.65%
Debt/Equity: 0.2
Revenue Growth: -11.6%
Profit Growth: -86.2%
EBITDA Margin: 20.99%
Operating Margin: 5.2%

## About
Dr Reddy's Labs is a leading Indian company in the Pharmaceuticals space, listed on the NSE. The company is a key player in the Pharma — Formulations segment with a strong market position and diversified operations.
Sector: Pharma
Industry: Drug Manufacturers - Specialty & Generic
Sub Industry: Pharma — Formulations

## Business Model
Overview: Dr Reddys Laboratories Ltd makes money through Core Business, Other Segments, Exports in Pharma — Formulations. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Source: Derived from stock data
Revenue Streams:
- Core Business
- Other Segments
- Exports
Operating Model:
- Develops, manufactures, distributes, or services healthcare products across regulated channels.
- Approvals, product mix, compliance quality, and R&D productivity shape growth.
Business Segments:
- Core Business: 70% of tracked revenue, equal to ₹22,793 Cr. | 70% | ₹22,793 Cr
- Other Segments: 27% of tracked revenue, equal to ₹8,791 Cr. | 27% | ₹8,791 Cr
- Exports: 3% of tracked revenue, equal to ₹977 Cr. | 3% | ₹977 Cr
Recent Context:
- Announcement: Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- Announcement: Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
- Business Wire: Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada

## Access
Current tier: anonymous
More history: Register free to see 8 more years.

## Data Freshness
Quote Updated: 2026-05-24T20:00:07.443Z
Price History Updated: 2026-05-25T05:26:30.359Z
Latest Price History Date: 2026-05-24
Technicals Updated: 2026-05-25T05:26:30.359Z
Quant Updated: 2026-05-25T05:26:30.359Z
Sentiment Updated: 2026-05-25T05:26:30.359Z
Financials Status: current
Financials Updated: 2026-05-18T02:34:25.780Z
Financials Last Attempt: 2026-05-18T02:34:25.780Z
Financials Provider Tried: yahoo
Latest P&L Period: FY25
Latest Balance Sheet Period: FY25
Latest Cash Flow Period: FY25

## P&L (Mar 2016)
Revenue: ₹15023 Cr
Operating Profit: ₹3508 Cr (OPM 23%)
Net Profit: ₹2336 Cr
Tax: ₹2900 Cr

## Annual P&L History
Mar 2016: Rev ₹15023Cr | PAT ₹2336Cr | OPM 23%
Mar 2017: Rev ₹15568Cr | PAT ₹2131Cr | OPM 23%
Mar 2018: Rev ₹14196Cr | PAT ₹1292Cr | OPM 17%

## Balance Sheet (Mar 2016)
Total Assets: ₹18457 Cr
Total Liabilities: ₹18457 Cr
Borrowings: ₹4314 Cr
Cash: ₹undefined Cr

## Shareholding
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%

## Board
- Gunupati Venkateswara Prasad B.E., Co-Chairman, MD & Member of Management Council
- Kallam Satish Reddy B.Tech., M.S., Chairman of the Board & Member of the Management Council
- Erez  Israeli M.B.A., CEO & Member of the Management Council
- Mannam  Venkatanarasimham, CFO & Member of the Management Council
- Krishna K. Venkatesh B.Pharma M.S., Global Head of IPDO, Integrated Product Development & Member of the Management Council

## Highlights
- Strong revenue growth of 15% CAGR over 5 years
- ROE of 11.8% indicates efficient capital allocation

## Concerns
- Debt-to-equity ratio needs monitoring amid expansion plans
- Promoter holding has seen slight decline in recent quarters

---
Source: rupiya.io/stocks/drreddy
Disclaimer: For research and education only. Not investment advice.